Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite
Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite
TORONTO, Aug. 21, 2023 /PRNewswire/ - Dan Legault, Chief Executive Officer and Director, Antibe Therapeutics Inc. (TSX: ATE) shares his Company's story in an interview with TMX Group.
多伦多，2023年8月21日/美通社/--安提贝治疗公司(多伦多证券交易所代码：ATE)首席执行官兼董事首席执行官丹·莱戈特在采访与TMX集团合作。
The View From The C-Suite video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange. Videos provide insight into how company executives think in the current business environment. To see the latest View From The C-Suite visit
来自C-Suite系列视频采访的观点突出了多伦多证券交易所和多伦多证券交易所创业板上市公司的独特视角。通过视频，您可以深入了解公司高管在当前商业环境中的想法。要查看C-Suite的最新视图，请访问
About Antibe Therapeutics (TSX: ATE)
关于安替比治疗公司(多伦多证券交易所市场代码：ATE)
Antibe Therapeutics is a clinical-stage biotech company developing next-generation, safer medicines for pain and inflammation. The company's proprietary drug platform is designed to overcome the gastrointestinal ulcers and bleeding associated with NSAIDs, a class of drugs used by most North Americans and by billions of people globally.
安提贝治疗公司是一家临床阶段的生物技术公司，开发下一代更安全的疼痛和炎症药物。该公司的专利药物平台旨在克服与非类固醇抗炎药相关的胃肠道溃疡和出血，非类固醇抗炎药是大多数北美人和全球数十亿人使用的一类药物。
CNW sponsored announcement. To learn more visit .
CNW赞助的公告。要了解更多信息，请访问。
SOURCE Toronto Stock Exchange
来源：多伦多证券交易所